<DOC>
	<DOCNO>NCT01653041</DOCNO>
	<brief_summary>Recipients live donor kidneys HLA-identical low risk acute rejection , graft loss death . There clear definition ideal immunosuppressive regimen population . Everolimus ( EVR ) associate low incidence viral infection also lowest incidence neoplasm . Furthermore , immunosuppressive regimen base everolimus allow reduction elimination calcineurin inhibitor reduce cardiovascular risk associate chronic use agent . Moreover , use EVR associate increased incidence proteinuria , associate mechanism fully elucidate . Knowing proteinuria may first indication recurrence underlie renal disease , detailed information patient 's medical history histological analysis graft may contribute additional knowledge area . The aim prospective , open , single arm study perform Hospital Rim e Hipertens√£o , investigate outcome kidney transplantation recipient HLA identical living donor , receive everolimus-based immunosuppressive regimen . This include 100 recipient first second kidney transplant live donor HLA identical Kidney Hypertension Hospital , follow period 12 month .</brief_summary>
	<brief_title>Certican ( Everolimus ) Recipients Kidney From HLA-identical Living Donors</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Adult candidate first repeat kidney transplant HLA identical living donor ; 2 . Patient sign informed consent form participate study ; 1 . Patients exclude receive immunosuppressive therapy transplantation ; 2 . Patients receive investigational medication within past 12 month ; 3 . Patients suspect known infection seropositive hepatitis B surface antigen ( HBsAg ) , antibody hepatitis B core antigen ( antiHBcAg ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) ; 4 . Patient cancer ( except nonmelanoma skin cancer ) within previous 2 year . 5 . Pregnant woman , nurse mother , woman childbearing potential use condoms oral contraceptive exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>immunosuppression , identical HLA , kidney transplantation , everolimus</keyword>
</DOC>